Drugs / 99mTc-HPArk2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04267900 | Dec 2019 → Dec 2020 | breast cancer | Peking Union Medical College Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc-HPArk2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04267900 ↗ |
| Modality | Diagnostic / imaging agent | “diagnostic performance and evaluation efficacy of 99mTc-HPArk2” NCT04267900 ↗ |